Knowledgebase

On Friday, 31 May, members of Control management of the Dutch Cancer Society visited NRG PALLAS at the Energy & Health Campus in Petten.

NRGIPALLAS and Curium have signed a long-term agreement to expand the current cooperation to include the production of lutetium-177 (Lu-177).

Representing Kansen voor West, Jeroen Elzenaar, Ruud van Raak en Tessa de Boer visited Petten to meet with Karlijn van der Schilden, Paula van der Vlies, Angelique de Boer-l'Istelle en Vinod Ramnandanlal. Aim was the final discussion for FIELD-LAB: one of the largest Kansen voor West II projects.

To promote collaboration and to inspire one another, FIELD-LAB hosted a partner meeting on the 26th of March at the Veranda in Amstelveen. Delegates of all partners were present to inform their fellow participants about their projects and share their expertise.

In a significant achievement for the field of radionuclide production, a dedicated team consisting of scientists of NRG|PALLAS and Future Chemistry, has successfully completed the SAT for their state-of-the-art, custom made Lu-177 no carrier added (n.c.a.) preparative High Performance Liquid Chromatography (prep-HPLC) system.

Last week, we gladly hosted the 33rd NKRV workshop at our premises in Petten. The mission of this Dutch Society for Clinical Radiochemistry (NKRV) is to stimulate research and education in radio(pharmaceutical)chemistry as well as the application of radiopharmaceuticals in the clinic.

After years of preparation, the FIELD-LAB facility in Petten, the Netherlands, has officially opened its doors on 7 December. This brand new facility will help accelerate the development of new nuclear medicines for the treatment of cancer.

Minister Kuipers of Health, Welfare and Sport announced today that there is full financing for the construction of the PALLAS-reactor in the North Holland town of Petten.

After many months of preparation and building, the new FIELD-LAB facility in Petten, the Netherlands, will open its doors on December 7th of this year. NRG|PALLAS has been working hard to realise the new drug discovery facility, that will help speed up the development and market launch of new nuclear drugs for cancer treatment.

NRG and TerThera signed an agreement for irradiation services in the High Flux Reactor in Petten, the Netherlands to produce Terbium-161. The non-carrier-added (NCA) Terbium-161 is produced by neutron irradiation of highly enriched Gadolinium-160 targets in the Dutch research reactor.